Car-t cell therapy with glofitamab for relapsed large b-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study tests a combination of CAR-T cell therapy and a drug called glofitamab for people with large B-cell lymphoma that has come back or not responded to treatment. The goal is to see if this combo can help those with high-risk features.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed type of large B-cell lymphoma that has come back or not responded to at least your first treatment.
- Your previous treatment included chemotherapy (like anthracycline) and an antibody therapy (like rituximab).
- You have at least one high-risk feature: lymphoma outside the lymph nodes, a tumor larger than 4 cm, or a TP53 gene mutation.
- You are generally able to care for yourself (ECOG score 0, 1, or 2).
- Your organs (liver, kidneys, lungs, heart, and blood) are working well enough for this treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination of medicines, chosen based on your tumor's specific features, for people whose lymphoma did not respond to CD19 CAR-T therapy. The goal is to find a more effective treatment option for this difficult situation.
This study looks at factors that predict how well CAR-T therapy works for large B-cell lymphoma that has come back or not responded to treatment. It aims to help doctors better identify who may benefit from this therapy.
This trial tests an experimental CAR T-cell therapy for people with large B-cell lymphoma that has come back or not responded to at least two prior treatments. The therapy uses a patient's own immune cells, modified to find and attack cancer cells.
This trial tests a combination of three drugs (polatuzumab vedotin, obinutuzumab, and glofitamab) for people with a type of large B-cell lymphoma. It is given either as a bridge treatment before CAR-T cell therapy or to those who did not fully respond to CAR-T.
This study tests a new CAR T-cell therapy for people with large B-cell lymphoma that has come back or not responded after at least two prior treatments, including an FDA-approved CAR T-cell therapy. The goal is to see if this new therapy can help when previous CAR T treatment has not worked.
This trial tests a combination of two immunotherapy drugs (rimegepant and glofitamab) plus a special cell therapy called CD19 CAR-T for people with large B-cell lymphoma that has not responded to or has returned after previous treatment. The goal is to see if this combination can better control the lymphoma and improve outcomes.
Hear when a new Large B-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.